GlassScriptPhysician profile
Carrie Burns
NPI 1952303299
$3,929.57
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $903 · 2021: $922 · 2022: $684 · 2023: $884 · 2024: $13.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $848 · Education: $49.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.84 |
| Education | $49.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $763.18 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $547.27 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.83 | 2020-2023 | Jardiance |
| Lilly USA, LLC | $404.49 | 2020-2023 | Mounjaro, Jardiance |
| Amarin Pharma, INC. | $332.29 | 2019-2021 | |
| Amgen INC. | $233.94 | 2020-2023 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $196.69 | 2019-2022 | |
| Abbott Laboratories | $139.80 | 2019-2023 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $130.44 | 2020-2023 | Nexletol |
| Pfizer INC. | $117.72 | 2020-2023 | |
| Radius Health, INC. | $95.64 | 2019-2020 | |
| Glaxosmithkline, LLC. | $86.14 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $70.84 | 2019-2021 | |
| Abbvie INC. | $68.76 | 2021-2022 | |
| Astellas Pharma US INC | $59.16 | 2021-2023 | Veozah, Myrbetriq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $40.51 | 2019-2020 | |
| Sanofi Pasteur INC. | $37.06 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $35.78 | 2021 | |
| Mannkind Corporation | $23.38 | 2019 | |
| Dexcom, INC. | $18.00 | 2023 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $16.17 | 2020 | |
| Genentech USA, INC. | $15.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.50 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.87 | 2024 | Qelbree |
| Currax Pharmaceuticals LLC | $11.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.